The Tyrosine Phosphatase hPTPRβ Controls the Early Signals and Dopaminergic Cells Viability via the P2X7 Receptor

ATP, one of the signaling molecules most commonly secreted in the nervous system and capable of stimulating multiple pathways, binds to the ionotropic purinergic receptors, in particular, the P2X7 receptor (P2X7R) and stimulates neuronal cell death. Given this effect of purinergic receptors on the viability of dopaminergic neurons model cells and that Ras GTPases control Erk1/2-regulated mitogen-activated cell proliferation and survival, we have investigated the role of the small GTPases of the Ras superfamily, together with their regulatory and effector molecules as the potential molecular intermediates in the P2X7R-regulated cell death of SN4741 dopaminergic neurons model cells. Here, we demonstrate that the neuronal response to purinergic stimulation involves the Calmodulin/RasGRF1 activation of the small GTPase Ras and Erk1/2. We also demonstrate that tyrosine phosphatase PTPRβ and other tyrosine phosphatases regulate the small GTPase activation pathway and neuronal viability. Our work expands the knowledge on the intracellular responses of dopaminergic cells by identifying new participating molecules and signaling pathways. In this sense, the study of the molecular circuitry of these neurons is key to understanding the functional effects of ATP, as well as considering the importance of these cells in Parkinson’s Disease.

[1]  F. Markwardt Human P2X7 receptors - properties of single ATP-gated ion channels. , 2020, Biochemical pharmacology.

[2]  P. Agostinho,et al.  Purinergic signaling orchestrating neuron-glia communication. , 2020, Pharmacological research.

[3]  A. Lucia,et al.  Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases , 2020, International journal of molecular sciences.

[4]  P. Illés P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases , 2020, International journal of molecular sciences.

[5]  H. Ulrich,et al.  The P2X7 Receptor: Central Hub of Brain Diseases , 2020, Frontiers in Molecular Neuroscience.

[6]  Antonio G. García,et al.  The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases , 2020, Medicinal research reviews.

[7]  H. Ulrich,et al.  P2Y6 and P2X7 Receptor Antagonism Exerts Neuroprotective/ Neuroregenerative Effects in an Animal Model of Parkinson’s Disease , 2019, Front. Cell. Neurosci..

[8]  S. Rohrbach,et al.  Role of PI3K/Akt and MEK/ERK Signalling in cAMP/Epac-Mediated Endothelial Barrier Stabilisation , 2019, Front. Physiol..

[9]  G. Bormans,et al.  Increased P2X7 Receptor Binding Is Associated With Neuroinflammation in Acute but Not Chronic Rodent Models for Parkinson’s Disease , 2019, Front. Neurosci..

[10]  Bing Lang,et al.  The Ras Superfamily of Small GTPases in Non-neoplastic Cerebral Diseases , 2019, Front. Mol. Neurosci..

[11]  A. Lucia,et al.  Epidermal growth factor receptor controls glycogen phosphorylase in T cells through small GTPases of the RAS family , 2019, The Journal of Biological Chemistry.

[12]  Mohammad Reza Ahmadian,et al.  Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms , 2018, Critical reviews in biochemistry and molecular biology.

[13]  Xiao-Guang Luo,et al.  Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson's disease , 2016, Molecular medicine reports.

[14]  J. Zugaza,et al.  Lck/PLCγ control migration and proliferation of interleukin (IL)-2-stimulated T cells via the Rac1 GTPase/glycogen phosphorylase pathway. , 2016, Cellular signalling.

[15]  G. Zheng,et al.  Expression and function of P2 receptors in hematopoietic stem and progenitor cells. , 2015, Stem cell investigation.

[16]  J. Zugaza,et al.  Guanine Nucleotide Exchange Factor αPIX Leads to Activation of the Rac 1 GTPase/Glycogen Phosphorylase Pathway in Interleukin (IL)-2-stimulated T Cells , 2015, The Journal of Biological Chemistry.

[17]  M. Herrero,et al.  Dyskinesia in Parkinson's disease: mechanisms and current non‐pharmacological interventions , 2014, Journal of neurochemistry.

[18]  R. Cunha,et al.  The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis , 2014, Neuropharmacology.

[19]  T. Deuel Anaplastic lymphoma kinase: "Ligand Independent Activation" mediated by the PTN/RPTPβ/ζ signaling pathway. , 2013, Biochimica et biophysica acta.

[20]  Yuxiang Wu,et al.  P2X3, but not P2X1, receptors mediate ATP-activated current in neurons innervating tooth-pulp , 2013, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[21]  F. Di Virgilio,et al.  The P2X7 receptor is a key modulator of aerobic glycolysis , 2012, Cell Death and Disease.

[22]  J. Zugaza,et al.  Rac1 Protein Regulates Glycogen Phosphorylase Activation and Controls Interleukin (IL)-2-dependent T Cell Proliferation* , 2012, The Journal of Biological Chemistry.

[23]  W. Becker,et al.  Extracellular ATP activates NFAT-dependent gene expression in neuronal PC12 cells via P2X receptors , 2011, BMC Neuroscience.

[24]  J. Stone Regulation and Function of the RasGRP Family of Ras Activators in Blood Cells. , 2011, Genes & cancer.

[25]  Yiming Zhu,et al.  Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions , 2011, Immunologic research.

[26]  K. Tufekci,et al.  The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease , 2011, Parkinson's disease.

[27]  G. Burnstock,et al.  Microglia: proliferation and activation driven by the P2X7 receptor. , 2010, The international journal of biochemistry & cell biology.

[28]  L. Minichiello TrkB signalling pathways in LTP and learning , 2009, Nature Reviews Neuroscience.

[29]  R. Palmer,et al.  Anaplastic lymphoma kinase: signalling in development and disease , 2009, The Biochemical journal.

[30]  Jian Feng,et al.  Parkin Protects Dopaminergic Neurons against Microtubule-depolymerizing Toxins by Attenuating Microtubule-associated Protein Kinase Activation* , 2009, Journal of Biological Chemistry.

[31]  B. Liu,et al.  The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery , 2008, Fundamental & clinical pharmacology.

[32]  C. Chu,et al.  Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress , 2008, Autophagy.

[33]  Y. Kong,et al.  Extracellular ATP Mediates Necrotic Cell Swelling in SN4741 Dopaminergic Neurons through P2X7 Receptors* , 2007, Journal of Biological Chemistry.

[34]  T. Mathivet,et al.  In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? , 2007, Cellular signalling.

[35]  Wei Zhang,et al.  Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. , 2007, The Journal of biological chemistry.

[36]  D. Donnelly-roberts,et al.  Discovery of P2X7 receptor‐selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states , 2007, British journal of pharmacology.

[37]  R. Heumann,et al.  Enhancement of dopaminergic properties and protection mediated by neuronal activation of Ras in mouse ventral mesencephalic neurones , 2007, The European journal of neuroscience.

[38]  T. Hagg,et al.  Protein tyrosine phosphatase inhibition reduces degeneration of dopaminergic substantia nigra neurons and projections in 6‐OHDA treated adult rats , 2007, The European journal of neuroscience.

[39]  Joffrey L. Degoutin,et al.  ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation , 2007, FEBS letters.

[40]  R. Schnellmann,et al.  A Death-Promoting Role for Extracellular Signal-Regulated Kinase , 2006, Journal of Pharmacology and Experimental Therapeutics.

[41]  K. Wada,et al.  Parkin potentiates ATP‐induced currents due to activation of P2X receptors in PC12 cells , 2006, Journal of cellular physiology.

[42]  I. Chessell,et al.  P2X7 receptors on microglial cells mediate injury to cortical neurons in vitro , 2006, Glia.

[43]  C. Créminon,et al.  Activation and Inhibition of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase by Monoclonal Antibodies and Absence of Agonist Activity of Pleiotrophin* , 2005, Journal of Biological Chemistry.

[44]  A. Sidhu,et al.  D1 Dopamine Receptor Mediates Dopamine-induced Cytotoxicity via the ERK Signal Cascade* , 2004, Journal of Biological Chemistry.

[45]  D. Burstein,et al.  Ectopic expression of murine diphosphoinositol polyphosphate phosphohydrolase 1 attenuates signaling through the ERK1/2 pathway. , 2004, Cellular signalling.

[46]  Hitoshi Sakuraba,et al.  ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth , 2004, Journal of Cell Science.

[47]  J. Kanellopoulos,et al.  The Pro-451 to Leu Polymorphism within the C-terminal Tail of P2X7 Receptor Impairs Cell Death but Not Phospholipase D Activation in Murine Thymocytes* , 2004, Journal of Biological Chemistry.

[48]  T. Oury,et al.  Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. , 2002, The American journal of pathology.

[49]  Kazuhide Inoue Microglial activation by purines and pyrimidines , 2002, Glia.

[50]  N. Rothwell,et al.  Extracellular ATP and P2X7 receptors in neurodegeneration. , 2002, European journal of pharmacology.

[51]  P. Ping,et al.  Mitochondrial PKCepsilon and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions and differential MAPK activation in PKCepsilon-induced cardioprotection. , 2002, Circulation research.

[52]  C. Coscia,et al.  Diversity of G Protein-Coupled Receptor Signaling Pathways to ERK/MAP Kinase , 2002, Neurosignals.

[53]  R. North Molecular physiology of P2X receptors. , 2002, Physiological reviews.

[54]  Miran Kim,et al.  Proteomic and functional evidence for a P2X7 receptor signalling complex , 2001, The EMBO journal.

[55]  B. Souttou,et al.  Activation of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Induces Neuronal Differentiation through the Mitogen-activated Protein Kinase Pathway* , 2001, The Journal of Biological Chemistry.

[56]  K. Adamsky,et al.  Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase β (RPTPβ) to tenascin C , 2001, Oncogene.

[57]  D. Ferrari,et al.  P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death , 1999, FEBS letters.

[58]  T. Joh,et al.  Neuroprotection and Neuronal Differentiation Studies Using Substantia Nigra Dopaminergic Cells Derived from Transgenic Mouse Embryos , 1999, The Journal of Neuroscience.

[59]  E. Martegani,et al.  The Ras Guanine nucleotide Exchange Factor CDC25Mm is present at the synaptic junction. , 1997, Experimental cell research.

[60]  Anirvan Ghosh,et al.  Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF , 1995, Nature.

[61]  Frank McCormick,et al.  The GTPase superfamily: conserved structure and molecular mechanism , 1991, Nature.

[62]  Peter P. Lee,et al.  Purinergic Signaling Within the Tumor Microenvironment. , 2021, Advances in experimental medicine and biology.

[63]  Kozo Kaibuchi,et al.  Role of Rho GTPases in thrombin-induced lung vascular endothelial cells barrier dysfunction. , 2004, Microvascular research.

[64]  K. Adamsky,et al.  Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTPbeta) to tenascin C. , 2001, Oncogene.